×
Please click
here
if you are not redirected within a few seconds.
All
News
Maps
Images
Videos
Shopping
Books
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
Archives
Sorted by relevance
Sorted by relevance
Sorted by date
RemeGen Co. Ltd. Schedules 2023 Annual Meeting - TipRanks.com
Tipranks
RemeGen Co. Ltd. Class H (HK:9995) has released an update. RemeGen Co., Ltd. has announced its 2023 Annual General Meeting (AGM) scheduled for June 28,...
2 hours ago
RemeGen Announces Continued Inclusion of Telitacicept and Disitamab Vedotin in China National Reimbursement ...
PR Newswire
PRNewswire/ -- RemeGen Co. Ltd. ("RemeGen" or "the Company") (9995.HK, SHA: 688331), a commercial-stage biotechnology company, has recently...
5 months ago
RemeGen Sets Shareholder Record Date for EGM Voting - TipRanks.com
Tipranks
RemeGen Co. Ltd. Class H (HK:9995) has released an update. RemeGen Co., Ltd. has announced the closure of its H Share register from June 12 to June 17,...
1 day ago
RemeGen Co., Ltd.'s (HKG:9995) Shares Climb 35% But Its Business Is Yet to Catch Up
Simply Wall Street
RemeGen Co., Ltd. ( HKG:9995 ) shareholders are no doubt pleased to see that the share price has bounced 35% in the...
1 month ago
RemeGen Celebrates World Lupus Day 2024 with Increased Lupus Visibility through Vital Knowledge Sharing
Citizen Tribune
The biotech company continues to offer hope to systemic lupus erythematosus (SLE) patients globally by sharing the latest developments of...
2 weeks ago
RemeGen's Telitacicept Shows Significant Promise in Phase II Trial for Primary Sjogren's Syndrome
Technology Networks
RemeGen Co., Ltd. announced that their Phase II clinical study of telitacicept for the treatment of Primary Sjögren's Syndromein adults has...
9 months ago
RemeGen Announces Publication of Results from Two Phase II Studies for Disitamab Vedotin in Latest Issue of Journal ...
PR Newswire
PRNewswire/ -- RemeGen Co. Ltd. ("RemeGen" or "the Company") (9995.HK, SHA: 688331), a commercial-stage biotechnology company,...
6 months ago
Remegen Gains in Hong Kong After US FDA Fast Tracks Chinese Firm's Sjögren's Syndrome Drug
Yicai Global
(Yicai) April 3 -- Remegen's Hong Kong-listed shares surged after the Chinese company said its innovative drug to treat Sjögren's syndrome received fast...
1 month ago
RemeGen's Pioneering RC88 Receives IND Approval from US FDA for Platinum-Resistant Recurrent Ovarian Cancer ...
PR Newswire
PRNewswire/ -- RemeGen Co. Ltd. ("RemeGen" or "the Company") (9995.HK, 688331.SH), a commercial-stage biotechnology company, announced that...
5 months ago
RemeGen Biosciences to Attend ASN Kidney Week 2022
BioSpace
Published: Nov 03, 2022. SOUTH SAN FRANCISCO, Calif., Nov. 3, 2022 /PRNewswire/ -- RemeGen Co., Ltd., a leading biopharmaceutical company with fully...
18 months ago